or Try an Advanced Search...

    Technical Analysis for MBRX - Moleculin Biotech, Inc.

    Grade Last Price % Change Price Change
    F 2.45 -5.77% -0.15
    MBRX closed down 5.77 percent on Friday, November 1, 2024, on 78 percent of normal volume. The stock fell below its 50 day moving average, damaging its intermediate-term outlook by crossing under that important trendline.
    Earnings due: Nov 11
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical MBRX trend table...
    Date Alert Name Type % Chg
    Fell Below 20 DMA Bearish 0.00%
    Fell Below 50 DMA Bearish 0.00%
    Outside Day Range Expansion 0.00%
    NR7 Range Contraction -5.77%
    Inside Day Range Contraction -5.77%
    Inside Day Range Contraction -3.54%
    Upper Bollinger Band Touch Strength -6.49%
    Gapped Up Strength -6.49%
    Upper Bollinger Band Touch Strength -6.49%
    20 DMA Support Bullish -3.54%
    Older End-of-Day Signals for MBRX ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High about 23 hours ago
    Up 1% about 23 hours ago
    10 DMA Resistance 1 day ago
    Down 1% 1 day ago
    Fell Below 10 DMA 1 day ago
    View Earlier Intraday Alerts

    Get this analysis on your stocks daily!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    MBRX Chart by TradingView
    Basic chart:

    Profile

    Moleculin Biotech, Inc., a preclinical and clinical-stage pharmaceutical company, focuses on the development of anti-cancer drug candidates. Its lead drug candidate is liposomal Annamycin, an anthracycline intended for the treatment of relapsed or refractory acute myeloid leukemia. The company also develops other drugs, including WP1066 Portfolio, a portfolio of small molecules targeting the modulation of transcription factors involved in cancer; and WP1122 Portfolio, a suite of molecules targeting the metabolic processes involved in cancer and glioblastoma. Moleculin Biotech, Inc. was founded in 2015 and is headquartered in Houston, Texas.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Cancer Pharmaceutical Oncology Acute Myeloid Leukemia Chemotherapy Antineoplastic Drugs Blastoma Glioblastoma Stage Pharmaceutical Transcription Transcription Factors Refractory Acute Myeloid Leukemia Transcription Factor Treatment Of Relapsed Or Refractory Acute Myeloid Leukemia

    Is MBRX a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Oct 9 Moleculin Biotech Inc (MBRX) Q2 2024 Earnings Call Highlights: Pivotal Phase 3 Trial for ...
    Oct 4 Moleculin to Present at Two Upcoming Investor Conferences
    Sep 23 Moleculin Announces Positive In Vivo Efficacy Data of Annamycin in Orthotopic and Experimental Lung Metastatic Models of Sarcoma
    Sep 16 Moleculin Participates in Virtual Investor "What this Means" Segment
    Sep 9 Moleculin Announces First Patients Treated in Phase 2 Clinical Trial of STAT3 Inhibitor in Combination with Radiation for the Treatment of Glioblastoma
    Aug 26 Moleculin to Present at LIVE! with Webull Corporate Connect: Healthcare Investment Webinar
    Aug 19 Moleculin Announces Closing of up to $16.5 Million Public Offering
    Aug 16 Moleculin prices up to $16.5M public offering
    Aug 16 Moleculin Announces Pricing of up to $16.5 Million Public Offering
    Aug 15 Moleculin Biotech GAAP EPS of -$1.70 beats by $0.74
    See more MBRX news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 15.75
    52 Week Low 2.115
    Average Volume 29,969
    200-Day Moving Average 4.60
    50-Day Moving Average 2.50
    20-Day Moving Average 2.51
    10-Day Moving Average 2.57
    Average True Range 0.20
    RSI (14) 45.95
    ADX 16.55
    +DI 18.33
    -DI 17.13
    Chandelier Exit (Long, 3 ATRs) 2.26
    Chandelier Exit (Short, 3 ATRs) 2.89
    Upper Bollinger Bands 2.70
    Lower Bollinger Band 2.33
    Percent B (%b) 0.34
    BandWidth 14.77
    MACD Line 0.01
    MACD Signal Line 0.01
    MACD Histogram 0.0028
    Fundamentals Value
    Market Cap 81.86 Million
    Num Shares 33.4 Million
    EPS -0.89
    Price-to-Earnings (P/E) Ratio -2.75
    Price-to-Sales 0.00
    Price-to-Book 0.48
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.83
    Resistance 3 (R3) 2.85 2.75 2.76
    Resistance 2 (R2) 2.75 2.65 2.74 2.74
    Resistance 1 (R1) 2.60 2.60 2.55 2.58 2.72
    Pivot Point 2.50 2.50 2.48 2.49 2.50
    Support 1 (S1) 2.35 2.40 2.30 2.33 2.18
    Support 2 (S2) 2.25 2.35 2.24 2.16
    Support 3 (S3) 2.10 2.25 2.14
    Support 4 (S4) 2.08